The recently published TRICOTEL phase 2 trial reported that atezolizumab plus vemurafenib and cobimetinib provided promising intracranial anti-tumor activity and acceptable toxicity in patients with BRAF(V600)-mutated melanoma (63). This evidence concerns the gene BRAF and melanoma.